CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioSpace
Original article

Shionogi makes $2B rare disease play with IntraBio buy

AqneursaPositive
AI Analysis

Summary

Shionogi announced the acquisition of IntraBio for $2 billion, gaining ownership of Aqneursa, a rare disease therapeutic with peak global sales potential of $1 billion across Niemann-Pick disease type C and ataxia-telangiectasia indications.

Importance:7/10
Sentiment:
0.60
M&Arare diseaseacquisitionNiemann-Pick diseaseataxia-telangiectasia
Related Companies

Read the original article

Published by BioSpace on October 6, 2026 2:22 PM

Read Original